Spruce Biosciences, Inc. (SPRB): Company Cash Funds

Official company branding of Spruce Biosciences (SPRB)

Spruce Biosciences focuses on therapies for rare endocrine pathologies with lifelong demand. The change in cash reserves on GURU.Markets confirms this trajectory, where the current status is 0.09. Patents for tildeserfone serve as a defense, creating barriers for competitors, although the absence of commercial sales due to trial stages deprives the company of pricing power.

Company Total Cash Volume: Spruce Biosciences, Inc. (SPRB) for 07/04/2022 - 11/21/2026

Analytical breakdowns for Spruce Biosciences

- stock value and consensus price forecast:
Fundamental company analysis:sprucebiosciences.com
Product sample of sprucebiosciences.com

This indicator tracks the volume of liquid assets, determining the issuer's ability to fund operating activities without external borrowing. Investors analyze the burn rate to calculate the "cash runway" until the product reaches the market. The trend in cash reserves allows for an assessment of the risk of equity dilution during subsequent offerings. For Spruce Biosciences (SPRB), this resource is critical as it completes the development of unique drugs for adrenal hyperplasia. The absence of competitors guarantees high future margins provided that current solvency is maintained.